A study, published July 12 in JCI Insight, suggests that PD-1 inhibitors could be successfully incorporated into early-stage non-small cell lung cancer treatment, according to new research by Weill Cornell Medicine and NewYork-Presbyterian investigators.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
